98 related articles for article (PubMed ID: 23503532)
1. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
[TBL] [Abstract][Full Text] [Related]
2. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
4. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.
Xhaard A; Rocha V; Bueno B; de Latour RP; Lenglet J; Petropoulou A; Rodriguez-Otero P; Ribaud P; Porcher R; Socié G; Robin M
Biol Blood Marrow Transplant; 2012 Mar; 18(3):406-13. PubMed ID: 21736868
[TBL] [Abstract][Full Text] [Related]
5. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
6. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
10. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
[TBL] [Abstract][Full Text] [Related]
11. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
12. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
13. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.
Bertz H; Spyridonidis A; Wäsch R; Grüllich C; Egger M; Finke J
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1563-70. PubMed ID: 19896080
[TBL] [Abstract][Full Text] [Related]
14. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
15. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.
Kebriaei P; Isola L; Bahceci E; Holland K; Rowley S; McGuirk J; Devetten M; Jansen J; Herzig R; Schuster M; Monroy R; Uberti J
Biol Blood Marrow Transplant; 2009 Jul; 15(7):804-11. PubMed ID: 19539211
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD.
Bertz H; Afting M; Kreisel W; Duffner U; Greinwald R; Finke J
Bone Marrow Transplant; 1999 Dec; 24(11):1185-9. PubMed ID: 10642806
[TBL] [Abstract][Full Text] [Related]
17. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
[TBL] [Abstract][Full Text] [Related]
19. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
20. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
